Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |||
---|---|---|---|---|---|---|
Aktuell sind keine Nachrichten verfügbar, die den gewählten Kriterien entsprechen. |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVONESIS | 57,82 | -0,10 % | Novozymes A/S: The era of biosolutions. Outlook upgraded for 2024 | Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased... ► Artikel lesen | |
GENMAB | 260,90 | -0,04 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2024 | Company Announcement Net sales of DARZALEX® in the second quarter of 2024 totaled USD 2,878 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN... ► Artikel lesen | |
ARBUTUS BIOPHARMA | 3,632 | +1,23 % | Arbutus Biopharma Corporation: Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 | WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology... ► Artikel lesen | |
MOLECULIN BIOTECH | 3,360 | -11,11 % | Moleculin Biotech, Inc. - S-1, General form for registration of securities | ||
BIOXCEL THERAPEUTICS | 1,070 | +0,56 % | BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI (dexmedetomidine) Sublingual Film | Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter... ► Artikel lesen | |
VERICEL | 49,000 | +1,66 % | Vericel Corporation: Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer | ||
SENSEI BIOTHERAPEUTICS | 0,614 | +0,99 % | Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 | - Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast... ► Artikel lesen | |
MUSTGROW BIOLOGICS | 0,486 | +0,62 % | MustGrow Biologics Corp.: MustGrow Accelerates California Sales and Marketing Efforts for TerraSante Biofertility Product | MustGrow to attend annual Strawberry Center Field Day at Cal Poly to promote biofertility product TerraSanteTM to hundreds of strawberry growers, researchers, and farming industry representatives.MustGrow... ► Artikel lesen | |
REGENXBIO | 13,400 | +1,52 % | REGENXBIO Inc.: REGENXBIO Announces Expansion of AFFINITY DUCHENNE Trial to Include a New Cohort of Younger Patients | Company to begin enrollment of patients aged 1-3 years
Expects data from younger cohort to be part of pivotal plans and BLA filing for broad label
End-of-Phase II meeting with FDA scheduled for... ► Artikel lesen | |
FENNEC PHARMACEUTICALS | 6,200 | +3,33 % | FRX Innovations Inc: Fennec Pharmaceuticals suspended by OSC | ||
AKEBIA | 1,401 | +5,98 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo (vadadustat) Tablets | Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and improve... ► Artikel lesen | |
REVANCE THERAPEUTICS | 4,000 | +10,50 % | Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update | NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.
Financial... ► Artikel lesen | |
ZEVRA THERAPEUTICS | 5,750 | 0,00 % | Zevra Therapeutics: Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C | CELEBRATION, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that the U.S. Food and... ► Artikel lesen | |
CORVUS PHARMACEUTICALS | 2,210 | -7,34 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results | Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell... ► Artikel lesen | |
CARTESIAN THERAPEUTICS | 15,200 | -1,30 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment... ► Artikel lesen |